Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pediatric tofacitinib induction and maintenance study in moderate to severe ulcerative colitis
2023-509694-22-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of tofacitinib in autoimmune colitis, sponsored by Pfizer. Primary endpoint: Remission by central read Mayo score at maintenance Week 44. Planned start Jan 2022; status: authorised.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-509694-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509694-22-00.